Compositions and methods for therapeutic delivery with frozen particles
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G06F-019/00
A61M-005/30
A61M-037/00
G06Q-050/22
A61K-009/14
G06F-019/18
출원번호
US-0290690
(2008-10-31)
등록번호
US-8793075
(2014-07-29)
발명자
/ 주소
Boyden, Edward S.
Hyde, Roderick A.
Leuthardt, Eric C.
Myhrvold, Nathan P.
Sweeney, Elizabeth A.
Wood, Jr., Lowell L.
출원인 / 주소
The Invention Science Fund I, LLC
인용정보
피인용 횟수 :
1인용 특허 :
173
초록▼
Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particula
Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.
대표청구항▼
1. A method, comprising: administering at least one solid frozen particle therapeutic composition including at least one tracer agent at high speed to at least one subject, and with use of at least one computing device, comparing information regarding at least one aspect of administering the at leas
1. A method, comprising: administering at least one solid frozen particle therapeutic composition including at least one tracer agent at high speed to at least one subject, and with use of at least one computing device, comparing information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition to the at least one subject based on the real-time feedback signal from the at least one tracer agent, and information regarding at least one clinical outcome following receipt by the at least one subject of at least one solid frozen particle therapeutic composition; andproviding output information regarding at least one aspect of the administering the at least one solid frozen particle therapeutic composition to the at least one subject based on the real-time feedback signal from the at least one tracer agent;wherein the output information is in the form of at least one of a code indicative of at least one vaccination delivered, a code indicative of at least one therapeutic agent delivered, a code indicative of at least one diagnostic agent delivered, a code indicative of at least one interaction of a delivered agent and at least one biological or chemical agent in the subject, a code indicative of at least one detection material delivered, a code indicative of the depth of penetration of a delivered agent, or a code indicative of the condition of at least one location of an administered frozen particle composition. 2. The method of claim 1, further including determining at least one statistical correlation. 3. The method of claim 1, further including counting the occurrence of at least one clinical outcome. 4. The method of claim 1, further including comparing information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition and the information regarding at least one clinical outcome based on the real-time feedback signal from the at least one tracer agent, before the administration of the at least one solid frozen particle therapeutic composition to another subject. 5. The method of claim 1, wherein the information regarding the at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding the amount of at least one solid frozen particle therapeutic composition or therapeutic agent administered to at least one biological tissue of a subject based on the real-time feedback signal from the at least one tracer agent. 6. The method of claim 1, wherein the information regarding the at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding at least one dimension of biological tissue penetration based on the real-time feedback signal from the at least one tracer agent. 7. The method of claim 6, wherein the information regarding the at least one dimension of biological tissue penetration includes information regarding at least one of depth, width, or breadth of administration of the at least one solid frozen particle therapeutic composition to the at least one biological tissue of at least one subject based on the real-time feedback signal from the at least one tracer agent. 8. The method of claim 1, wherein the information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding two or more subjects with one or more common attributes. 9. The method of claim 8, wherein the one or more common attributes include genetic attributes, mental attributes, or psychological attributes. 10. The method of claim 8, wherein the one or more common attributes include genotype attributes or phenotype attributes. 11. The method of claim 10, wherein the one or more common attributes include at least one of height; weight; medical diagnosis; familial background; results on one or more medical tests; ethnic background; body mass index; age; presence or absence of at least one disease or condition; species; ethnicity; race; allergies; gender; thickness of epidermis; thickness of dermis; thickness of stratum corneum; keratin deposition; collagen deposition; blood vessel condition; skin condition; hair or fur condition; muscle condition; tissue condition; organ condition; nerve condition; brain condition; presence or absence of at least one biological, chemical, or therapeutic agent in the subject; pregnancy status; lactation status; genetic profile; proteomic profile; partial or whole genetic sequence; partial or whole proteomic sequence; medical history; or blood condition. 12. The method of claim 1, wherein the output information includes at least one of a response signal, a comparison code, a comparison plot, a diagnostic code, a treatment code, a test code, a code indicative of at least one treatment received, a code indicative of at least one prescribed treatment step, a code indicative of at least one vaccination administered; a code indicative of at least one therapeutic agent administered; a code indicative of at least one diagnostic agent administered; a code indicative of at least one interaction of a administered agent and at least one biological or chemical agent in the subject; a code indicative of at least one dispersion or location of at least one administered agent; a code indicative of at least one detection material administered; a code indicative of the depth of penetration of an administered agent; or a code indicative of the condition of at least one location of an administered solid frozen particle composition. 13. The method of claim 1, wherein the information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding at least one cellular or tissue source. 14. The method of claim 13, wherein the information regarding at least one cellular or tissue source includes information regarding at least one abnormal cellular or tissue source. 15. The method of claim 13, wherein the information regarding at least one cellular or tissue source includes information regarding at least one type of cell or tissue. 16. The method of claim 1, wherein the at least one solid frozen particle therapeutic composition includes at least one of nitrogen, carbon dioxide, hydrogen oxide, helium, neon, xenon, krypton, air, oxygen, chlorine, bromine, argon, polyethylene glycol, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, acetic acid, benzene, carbon tetrachloride, acetonitrile, hexane, methylene chloride, carboxylic acid, saline, Ringer's solution, lactated Ringer's solution, Hartmann's solution, acetated Ringer's solution, phosphate buffered solution, TRIS-buffered saline solution, Hank's balanced salt solution, Earle's balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, or diethyl ether. 17. The method of claim 1, wherein the at least one solid frozen particle composition includes at least one major dimension of approximately one centimeter or less, approximately one millimeter or less, approximately one micrometer or less, approximately one nanometer or less, or any value therebetween. 18. The method of claim 1, wherein the at least one solid frozen particle therapeutic composition includes one or more reinforcement agents. 19. The method of claim 1, wherein the at least one solid frozen particle therapeutic composition includes one or more explosive materials. 20. The method of claim 1, wherein the receipt by the at least one subject of the at least one solid frozen particle therapeutic composition is pursuant to at least one clinical trial. 21. The method of claim 1, further including creating at least one inclusion criterion and at least one exclusion criterion for a clinical trial involving the at least one solid frozen particle therapeutic composition. 22. The method of claim 1, wherein comparing the information further includes suggesting the inclusion of one or more of the at least one subject in at least one clinical trial. 23. The method of claim 1, wherein comparing the information further includes suggesting the exclusion of one or more of the at least one subject in at least one clinical trial. 24. The method of claim 1, further including using one or more comparisons to predict at least one clinical outcome regarding at least one second subject. 25. The method of claim 24, wherein the at least one second subject has not received the at least one solid frozen particle therapeutic composition. 26. The method of claim 24, further including predicting at least one clinical outcome involving the at least one second subject, wherein the at least one second subject is a plurality of people; and segregating subject identifiers associated with the plurality of people in reference to the predicted at least one clinical outcome. 27. The method of claim 24, further including determining the eligibility of the at least one second subject for at least one clinical trial. 28. A method of predicting a clinical outcome of administering at least one solid frozen particle therapeutic composition to at least one biological tissue of at least one first subject, comprising: administering at high speed at least one solid frozen particle therapeutic composition including at least one tracer agent, to at least one biological tissue of at least one first subject and to at least one biological tissue of at least one second subject, and with the use of at least one computing device, determining a similarity or a dissimilarity in information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition to the at least one biological tissue of the at least one first subject to information regarding at least one aspect of administering at least one solid frozen particle therapeutic composition to the at least one biological tissue of the at least one second subject based on real-time feedback of the detected at least one tracer agent, wherein the at least one second subject attained a clinical outcome following receipt of the at least one solid frozen particle therapeutic composition; andproviding output information regarding at least one aspect of the administering the at least one solid frozen particle therapeutic composition to the at least one biological tissue of at least one subject based on the real-time feedback signal from the at least one tracer agent. 29. The method of claim 28, wherein the information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding amount of at least one solid frozen particle therapeutic composition or therapeutic agent administered to at least one biological tissue of at least one subject based on the real-time feedback signal from the at least one tracer agent. 30. The method of claim 28, wherein the output information is based on the determination. 31. The method of claim 28, wherein the information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding at least one dimension of biological tissue penetration based on the real-time feedback signal from the at least one tracer agent. 32. The method of claim 31, wherein the information regarding at least one dimension of biological tissue penetration includes information regarding at least one of depth, width, or breadth of administration of at least one solid frozen particle therapeutic composition to at least one biological tissue of at least one subject based on the real-time feedback signal from the at least one tracer agent. 33. The method of claim 28, wherein the information regarding at least one aspect of administering the at least one solid frozen particle therapeutic composition includes information regarding two or more subjects with one or more common attributes. 34. The method of claim 33, wherein the one or more common attributes include genetic attributes, mental attributes, or psychological attributes. 35. The method of claim 33, wherein the one or more common attributes include genotype attributes or phenotype attributes. 36. The method of claim 35, wherein the one or more common attributes include at least one of height; weight; medical diagnosis; familial background; medical history; results on one or more medical tests; ethnic background; body mass index; age; presence or absence of at least one disease or condition; species; ethnicity; race; allergies; gender; thickness of epidermis; thickness of dermis; thickness of stratum corneum; keratin deposition; collagen deposition; lymph condition; blood vessel condition; skin condition; hair or fur condition; muscle condition; tissue condition; organ condition; nerve condition; brain condition; presence or absence of at least one biological, chemical, or therapeutic agent in the subject; pregnancy status; lactation status; genetic profile; proteomic profile; partial or whole genetic sequence; partial or whole proteomic sequence; or blood condition. 37. The method of claim 28, wherein the output information includes at least one of a response signal, a comparison code, a comparison plot, a diagnostic code, a treatment code, a test code, a code indicative of at least one treatment received, a code indicative of at least one prescribed treatment step, a code indicative of at least one vaccination administered; a code indicative of at least one therapeutic agent administered; a code indicative of at least one diagnostic agent administered; a code indicative of at least one interaction of a administered agent and at least one biological or chemical agent in the subject; a code indicative of at least one dispersion or location of at least one administered agent; a code indicative of at least one detection material administered; a code indicative of the depth of penetration of an administered agent; or a code indicative of the condition of at least one location of an administered solid frozen particle therapeutic composition. 38. The method of claim 28, wherein the information regarding at least one aspect of administering at least one solid frozen particle therapeutic composition includes information regarding at least one cellular or tissue source. 39. The method of claim 38, wherein the information regarding at least one cellular or tissue source includes information regarding at least one abnormal cellular or tissue source. 40. The method of claim 38, wherein the information regarding at least one cellular or tissue source includes information regarding at least one type of cell or tissue. 41. The method of claim 28, wherein the at least one solid frozen particle therapeutic composition includes at least one of nitrogen, carbon dioxide, hydrogen oxide, helium, neon, xenon, krypton, air, oxygen, chlorine, bromine, argon, polyethylene glycol, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, acetic acid, benzene, carbon tetrachloride, acetonitrile, hexane, methylene chloride, carboxylic acid, saline, Ringer's solution, lactated Ringer's solution, Hartmann's solution, acetated Ringer's solution, phosphate buffered solution, TRIS-buffered saline solution, Hank's balanced salt solution, Earle's balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, or diethyl ether. 42. The method of claim 28, wherein the at least one solid frozen particle therapeutic composition includes at least one major dimension of approximately one centimeter or less, approximately one millimeter or less, approximately one micrometer or less, approximately one nanometer or less, or any value therebetween. 43. The method of claim 28, wherein the at least one solid frozen particle therapeutic composition includes one or more reinforcement agents. 44. The method of claim 28, wherein the at least one solid frozen particle therapeutic composition includes one or more explosive agents. 45. The method of claim 28, wherein the receipt by the at least one subject of at least one solid frozen particle therapeutic composition is pursuant to at least one clinical trial. 46. The method of claim 28, further including determining at least one correlation before the administration of the at least one solid frozen particle therapeutic composition. 47. The method of claim 28, further including creating at least one inclusion criterion and at least one exclusion criterion for a clinical trial involving the at least one solid frozen particle therapeutic composition. 48. The method of claim 28, further including suggesting the inclusion of one or more of the at least one subject in at least one clinical trial. 49. The method of claim 28, further including suggesting the exclusion of one or more of the at least one subject in at least one clinical trial. 50. The method of claim 28, further including using one or more of the at least one determination to predict at least one clinical outcome regarding at least one second subject. 51. The method of claim 50, wherein the at least one second subject has not received the at least one solid frozen particle therapeutic composition. 52. The method of claim 50, wherein using one or more of the at least one comparison further includes predicting at least one clinical outcome involving the at least one second subject, wherein the at least one second subject is a plurality of people; and segregating subject identifiers associated with the plurality of people in reference to the predicted at least one clinical outcome. 53. The method of claim 51, further including determining the eligibility of the at least one second subject for at least one clinical trial.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (173)
Phillips William T. (San Antonio TX) Klipper Robert W. (San Antonio TX) Timmons James H. (Tacoma WA) Rudolph Alan S. (Bowie MD), 99m TC labeled liposomes.
Smits Georges (Gijzegem-Aalst BEX) Daenekindt Luc (Gijzegem-Aalst BEX) Booten Karl (Geetbets BEX), Agglomerated composition, process for producing it and food products containing the said composition.
Kleiner Fredric (New City NY) Roy PradipK. (Yorktown NY), Apparatus and process for the preparation of gasified confectionaries by pressurized deposit molding.
Opel Alan E. (Monrovia CA) Spivak Philip (Toluca Lake CA) Zadorozhny Oleg (North Hollywood CA), Apparatus for producing and blasting sublimable granules on demand.
Armstrong Jay (1543 Weymouth Cir. ; Apt. 109 Westlake OH 44145) Becker James R. (6272 Mills Creek La. North Ridgeville OH 44039), Blast cleaning system.
Topalian Harry H. (Dover DE) Wyss Clement R. (Lewes DE) Kenyon Ralph E. (Dover DE) Dec Anthony F. (Dover DE), Frozen aerated ready-to-eat gelatin composition.
Kitamura Hiroshi (Shizuoka JPX) Mitsuuchi Masamichi (Shizuoka JPX), Glass-reinforced thermoplastic resin compositions containing the anatase form of titanium dioxide as a white pigmenting.
Brinegar Chris (587 Locksley Rd. Boulder Creek CA 95006) Gilmore James (6385 Camino Verde Dr. San Jose CA 95119) Johnson Michael (6385 Camino Verde Dr. San Jose CA 95119) Walker Nigel (5385 Broadway , Ice-mediated introduction of substances into biological material.
Thomas Dag Horn ; Sandra Marchese Johnson, Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction.
Rahman Aquilur (Gaithersburg MD) Rafaeloff Rafael (Tel-Aviv MD ILX) Husain Syed R. (Gaithersburg MD), Liposome encapsulated taxol and a method of using the same.
Weaver, James C.; Anderson, R. Rox; Herndon, Terry O; Gowrishankar, T. R.; Gift, Elizabeth A.; Gonzalez, Salvador, Localized molecular and ionic transport to and from tissues.
Poulsen, Jens Ulrik; Christensen, Lars Hofmann; Aasmul, S.o slashed.ren, Method and a system for assisting a user in a medical self treatment, said self treatment comprising a plurality of actions.
Power Wendy ; Reed Michael A. ; Frustaci Dominick J. ; Larocque Gerald ; Marchetti Brenda, Method and apparatus for determining quantity of liquid in a container and/or lack of motion thereof.
Westergaard Knud E. (Rolighedsvej 16 9560 Hadsund DKX), Method and apparatus for particle blasting using particles of a material that changes its state.
Frohlich, Hans; Gebhardt, Sabine; Trampusch, Berthold, Method and device for generating a two-phase gas-particle jet, in particular containing CO2 dry ice particles.
Cates Michael C. (Solana Beach CA) Hamm Richard R. (San Diego CA) Lewis Michael W. (Wichita KS) Schmitz Wayne N. (St. Louis MO), Method and system for removing a coating from a substrate using radiant energy and a particle stream.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Method for transporting substances into living cells and tissues and apparatus therefor.
Bellhouse Brian J. (Islip GB2) Sarphie David F. (Witney GB2) Greenford John C. (Abingdon GB2), Method of delivering powder transdermally with needless injector.
Costantino Henry R. ; Jaworowicz Warren E. ; Tracy Mark A. ; Beganski Christopher P., Method of producing sub-micron particles of biologically active agents and uses thereof.
Cummins Thomas J. (Rochester NY) Ekeze Tobias D. (Rochester NY), Methods of extracting nucleic acids and PCR amplification without using a proteolytic enzyme.
Rhim Won-Kyu (Pasadena CA) Hyson Michael T. (Glendale CA) Chung Sang-Kun (Diamond Bar CA) Colvin Michael S. (Malibu CA) Chang Manchium (Los Angeles CA), Monodisperse, polymeric microspheres produced by irradiation of slowly thawing frozen drops.
Shih, Hong; Leonte, Oana M.; Daugherty, John E.; Huang, Tuochuan; Goldspring, Gregory J.; May, Michael C., On-line chamber cleaning using dry ice blasting.
Clark ; Jr. William G. (Murrysville PA) Herald John J. (Monroeville PA) Liaw Peter K. (Knoxville TN), Pressurized ferrofluid paint removal system using an electromagnet and eddy current encircling coil to adjust weight per.
Fages Jacques,FRX ; Marty Alain,FRX ; Combes Didier,FRX ; Condoret Jean-Stephane,FRX, Process for treating bone tissue and corresponding implantable biomaterials.
Clauss Steven L. (Manville NJ) Pastel Michael J. (Highland Mills NY) Zawadzki Rainer K. (Wuhan CNX), Stable porfimer sodium compositions and methods for their manufacture.
Boyden, Edward S.; Cook, Daniel B.; Hyde, Roderick A.; Leuthardt, Eric C.; Myhrvold, Nathan P.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Systems, devices, and methods for making or administering frozen particles.
Santa Cruz Cathy D. ; Deniston-Korgol Christine L. ; Baugh Barbara I. ; Baugh Alexandria D. ; Baugh Roger D., Weather-proof wrist, forearm, and elbow protectors.
Dean ; Jr. Robert C. (Norwich VT) Silver Frederick H. (Long Valley NJ) Berg Richard A. (Lambertville NJ) Phillips Philip G. (Norwich VT) Runstadler ; Jr. Peter W. (Hanover NH), Weighted collagen microsponge for immobilizing bioactive material.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.